DekaBank Deutsche Girozentrale Invests $159,000 in Alkermes plc $ALKS

DekaBank Deutsche Girozentrale acquired a new position in Alkermes plc (NASDAQ:ALKS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,614 shares of the company’s stock, valued at approximately $159,000.

Other institutional investors have also recently modified their holdings of the company. Intech Investment Management LLC raised its position in Alkermes by 25.6% during the first quarter. Intech Investment Management LLC now owns 85,564 shares of the company’s stock valued at $2,825,000 after acquiring an additional 17,413 shares in the last quarter. Baird Financial Group Inc. purchased a new position in Alkermes during the first quarter valued at approximately $587,000. Victory Capital Management Inc. raised its position in Alkermes by 30.9% during the first quarter. Victory Capital Management Inc. now owns 120,997 shares of the company’s stock valued at $3,995,000 after acquiring an additional 28,596 shares in the last quarter. GAMMA Investing LLC raised its position in Alkermes by 31.9% during the first quarter. GAMMA Investing LLC now owns 5,396 shares of the company’s stock valued at $178,000 after acquiring an additional 1,305 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Alkermes by 2,422.0% during the first quarter. Acadian Asset Management LLC now owns 881,827 shares of the company’s stock valued at $29,100,000 after acquiring an additional 846,861 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Alkermes Price Performance

Alkermes stock opened at $29.72 on Tuesday. The stock has a market capitalization of $4.91 billion, a PE ratio of 14.29, a price-to-earnings-growth ratio of 1.61 and a beta of 0.54. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.45. The business has a 50 day simple moving average of $29.44 and a 200-day simple moving average of $29.16.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. The business had revenue of $390.66 million during the quarter, compared to analysts’ expectations of $343.20 million. Alkermes had a return on equity of 24.86% and a net margin of 23.15%.The business’s revenue was down 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.16 earnings per share. On average, equities research analysts anticipate that Alkermes plc will post 1.31 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on ALKS shares. The Goldman Sachs Group started coverage on Alkermes in a research report on Tuesday, July 15th. They set a “buy” rating and a $43.00 price target for the company. Royal Bank Of Canada lifted their price target on Alkermes from $45.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. lifted their price target on Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Alkermes in a research report on Tuesday, October 14th. Finally, Zacks Research upgraded Alkermes from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 22nd. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $43.25.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $31.53, for a total value of $283,770.00. Following the sale, the executive vice president directly owned 73,740 shares of the company’s stock, valued at $2,325,022.20. The trade was a 10.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.40% of the stock is owned by corporate insiders.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.